Literature DB >> 24200825

Network Oncology (NO)--a clinical cancer register for health services research and the evaluation of integrative therapeutic interventions in anthroposophic medicine.

Friedemann Schad1, Jan Axtner, Antje Happe, Thomas Breitkreuz, Constantin Paxino, Johannes Gutsch, Burkhard Matthes, Marion Debus, Matthias Kröz, Günther Spahn, Hartmut Riess, Hans-Broder von Laue, Harald Matthes.   

Abstract

BACKGROUND: Concepts of integrative oncology (IO), as have been offered by anthroposophic medicine (AM) for decades, are gaining increasing interest and acceptance. Central aspects are multimodal therapeutic interventions, health-related quality of live, and patients' preference as well as therapeutic relationship and clinical outcome. Despite its broad application, IO lacks evaluation in clinical practice and complementary therapies are not monitored by any cancer registries.
METHODS: To close this gap we established 'Network Oncology' (NO), a conjoint registry of German outpatient AM practitioners and AM hospitals. In this paper we present the project and a first data overview and compare it to epidemiological registers and current literature.
RESULTS: NO has collected 10,405 cancer patients' records in 6 years. Compared to epidemiological registers our data show minor differences in disease entity distribution, age, and gender. There is an overproportional amount of young breast cancer patients in NO institutions indicating a demand for integrative therapies in this group. There is no difference between the UICC (Union for International Cancer Control) stages at first diagnosis and at admission to a NO facility. According to our data conventional therapies were less frequently administered after admission to a NO facility. Nevertheless, one third of the patients received their first conventional therapy in a NO facility. 80% of the patients received mistletoe preparations and 63% had nonpharmacotherapeutic, complementary interventions.
CONCLUSION: Integrative oncological approaches attract a great number of patients visiting AM institutions. The NO provides an infrastructure to evaluate integrative interventions in AM, allows comparison to other clinical registers, and thus can contribute to health service research in this field.
© 2013 S. Karger GmbH, Freiburg.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24200825     DOI: 10.1159/000356204

Source DB:  PubMed          Journal:  Forsch Komplementmed        ISSN: 1661-4119


  18 in total

1.  Assessment of integrative non-pharmacological interventions and quality of life in breast cancer patients using real-world data.

Authors:  Shiao Li Oei; Anja Thronicke; Harald Matthes; Friedemann Schad
Journal:  Breast Cancer       Date:  2021-01-03       Impact factor: 4.239

2.  Evaluation of the effects of integrative non-pharmacological interventions on the internal coherence and resilience of breast cancer patients.

Authors:  Shiao Li Oei; Anja Thronicke; Harald Matthes; Friedemann Schad
Journal:  Support Care Cancer       Date:  2020-07-15       Impact factor: 3.603

3.  Adverse Drug Reactions and Expected Effects to Therapy with Subcutaneous Mistletoe Extracts (Viscum album L.) in Cancer Patients.

Authors:  Megan L Steele; Jan Axtner; Antje Happe; Matthias Kröz; Harald Matthes; Friedemann Schad
Journal:  Evid Based Complement Alternat Med       Date:  2014-01-19       Impact factor: 2.629

4.  Safety of Intravenous Application of Mistletoe (Viscum album L.) Preparations in Oncology: An Observational Study.

Authors:  Megan L Steele; Jan Axtner; Antje Happe; Matthias Kröz; Harald Matthes; Friedemann Schad
Journal:  Evid Based Complement Alternat Med       Date:  2014-05-15       Impact factor: 2.629

5.  Health services research of integrative oncology in palliative care of patients with advanced pancreatic cancer.

Authors:  Jan Axtner; Megan Steele; Matthias Kröz; Günther Spahn; Harald Matthes; Friedemann Schad
Journal:  BMC Cancer       Date:  2016-08-02       Impact factor: 4.430

6.  Clinical safety of combined therapy of immune checkpoint inhibitors and Viscum album L. therapy in patients with advanced or metastatic cancer.

Authors:  Anja Thronicke; Megan L Steele; Christian Grah; Burkhard Matthes; Friedemann Schad
Journal:  BMC Complement Altern Med       Date:  2017-12-13       Impact factor: 3.659

7.  Safety of Combined Treatment With Monoclonal Antibodies and Viscum album L Preparations.

Authors:  Friedemann Schad; Jan Axtner; Matthias Kröz; Harald Matthes; Megan L Steele
Journal:  Integr Cancer Ther       Date:  2016-12-01       Impact factor: 3.279

8.  Cost-effectiveness of real-world administration of chemotherapy and add-on Viscum album L. therapy compared to chemotherapy in the treatment of stage IV NSCLC patients.

Authors:  Anja Thronicke; Thomas Reinhold; Philipp von Trott; Christian Grah; Burkhard Matthes; Harald Matthes; Friedemann Schad
Journal:  PLoS One       Date:  2020-07-27       Impact factor: 3.240

Review 9.  Economic Evaluation of Complementary and Alternative Medicine in Oncology: Is There a Difference Compared to Conventional Medicine?

Authors:  Jutta Huebner; Franz J Prott; Ralph Muecke; Christoph Stoll; Jens Buentzel; Karsten Muenstedt; Oliver Micke
Journal:  Med Princ Pract       Date:  2016-09-07       Impact factor: 1.927

10.  The Internal Coherence of Breast Cancer Patients Is Associated with the Decision-Making for Chemotherapy and Viscum album L. Treatment.

Authors:  Shiao Li Oei; Anja Thronicke; Matthias Kröz; Cornelia Herbstreit; Friedemann Schad
Journal:  Evid Based Complement Alternat Med       Date:  2018-09-27       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.